Atlas Trials

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Clinical trial NCT05190445 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05190445
Sponsor
Pieris Pharmaceuticals, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Gastric Cancer
Start date
2021-11-01
Primary completion
2023-02-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.